W. Bradford Smith's Insider Trades & SAST Disclosures
W. Bradford Smith's most recent trade in Lyra Therapeutics Inc was a trade of 30,000 Stock Option done . Disclosure was reported to the exchange on June 13, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern W. Bradford Smith.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyra Therapeutics Inc | W. Bradford Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 30,000 | 30,000 | - | - | Stock Option | |
| Lyra Therapeutics Inc | W. Bradford Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option | |
| Q32 Bio Inc. | W. Bradford Smith | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 213,000 | 213,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc. | W. Bradford Smith | See remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 36,000 | 36,000 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | W. Bradford Smith | See Remarks | Sale of securities on an exchange or to another person at price $ 1.39 per share. | 09 Jan 2023 | 3,729 | 14,219 (0%) | 0% | 1.4 | 5,188 | Common Stock |
| Q32 Bio Inc. | W. Bradford Smith | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,930 | 17,948 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc. | W. Bradford Smith | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,930 | 14,070 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | W. Bradford Smith | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,600 | 6,800 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | W. Bradford Smith | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2023 | 6,600 | 11,018 (0%) | 0% | - | Common Stock | |
| Lyra Therapeutics Inc | W. Bradford Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 7,250 | 7,250 | - | - | Stock Option | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 126,000 | 126,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2022 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 6,600 | 13,400 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2022 | 6,600 | 6,600 (0%) | 0% | - | Common Stock | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 3.78 per share. | 01 Jan 2022 | 2,182 | 4,418 (0%) | 0% | 3.8 | 8,248 | Common Stock |
| Lyra Therapeutics Inc | W. Bradford Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 7,250 | 7,250 | - | - | Stock Option | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 122,000 | 122,000 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 14.25 per share. | 05 Feb 2021 | 13,500 | 0 (0%) | 0% | 14.3 | 192,425 | Common Stock |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2021 | 13,500 | 101,904 | - | - | Employee Stock Option (Right to Buy) | |
| Q32 Bio Inc. | W. Bradford Smith | CFO & Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 05 Feb 2021 | 13,500 | 13,500 (0%) | 0% | 0.6 | 8,640 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges